GoPubMed Proteins lists recent and important papers and reviews for
proteins. Page last changed on 19 Dec 2016.
Von Hippel-Lindau tumor suppressor
VHL, pVHL, von Hippel-Lindau tumor suppressor
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008] (from
NCBI)
Sponsored links
Top mentioned proteins:
CAN, XRCC1, HAD, vascular endothelial growth factor, V1a
Papers using
VHL
antibodies
TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis
Supplier
In British Journal of Cancer, 2007
... cell carcinoma cell lines (RCC4) stably transfected with pcDNA3 (an empty vector) and pcDNA3-VHL (a VHL-expressing vector), respectively, were purchased from DS Pharma Biomedical (Osaka, Japan) ...
VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400
Supplier
In Oncogene, 2007
... Anti-VHL (Ig32) was purchased from BD Pharmingen, anti-HA (Y-11), anti-cyclin B1, anti-cdc27 and anti-VHL (FL-181) antibodies were purchased from Santa Cruz Biotechnology, and anti-myc (9E10) antibody ...
The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells
Supplier
In Oncogene, 2006
... (Santa Cruz, CA, USA); Phospho-Erk1/2 and Erk1/2 antibodies from Zymed Laboratories (San Francisco, CA, USA); VHL antibodies from BD Biosciences (San Jose, CA, USA) ...
C-terminal modifications regulate MDM2 dissociation and nuclear export of p53.
Supplier
In PLoS ONE, 2006
TRAF6-mediated ubiquitination regulates nuclear translocation of NRIF, the p75 receptor interactor.
more suppliersSupplier
In PLoS ONE, 2004
... pVHL antibody was from BD Biosciences (Bedford, MA) ...
Papers on
VHL
Axitinib for the treatment of metastatic renal cell carcinoma.
Review
New
Cleveland, United States. In Future Oncol, Feb 2016
UNASSIGNED: Renal cell carcinoma is a cancer that results from a genetic inactivation of the VHL tumor suppressor gene leading to an upregulation of VEGF.
An ID2-dependent mechanism for VHL inactivation in cancer.
New
Impact
New York City, United States. In Nature, Feb 2016
ID2 binds to the VHL ubiquitin ligase complex, displaces VHL-associated Cullin 2, and impairs HIF2α ubiquitylation and degradation.
Hypoxia Promotes Cancer Stem Cells via ID2-Dependent VHL Inactivation.
New
In Cancer Discov, Feb 2016
UNASSIGNED: Hypoxia inactivates DYRK1, preventing ID2 phosphorylation and promoting CSCs and HIF2α stabilization.
Formation of renal cysts and tumors in Vhl/Trp53-deficient mice requires HIF-1α and HIF-2α.
New
Zürich, Switzerland. In Cancer Res, Feb 2016
UNASSIGNED: The von Hippel-Lindau (VHL) tumor suppressor gene is inactivated in the majority of clear cell renal cell carcinomas (ccRCC), but genetic ablation of Vhl alone in mouse models is insufficient to recapitulate human tumorigenesis.
Von Hippel-Lindau disease: an evaluation of natural history and functional disability.
New
Modena, Italy. In Neuro Oncol, Feb 2016
BACKGROUND: Although many studies have been published about specific lesions characterizing von Hippel-Lindau(VHL) disease, none have dealt with the natural history of the whole disease and the consequent disabilities.
Identification of DNA methylation-independent epigenetic events underlying clear cell renal cell carcinoma.
New
United States. In Cancer Res, Feb 2016
Compared to commonly mutated genes in ccRCC, such as the von Hippel-Lindau (VHL) tumor suppressor, the genes identified by AcceSssIble comprised distinct pathways and more frequently underwent epigenetic changes, suggesting that genetic and epigenetic alterations could be independent events in ccRCC.
Down-regulation of C12orf59 is associated with a poor prognosis and VHL mutations in renal cell carcinoma.
New
Shenzhen, China. In Oncotarget, Feb 2016
VHL non-sense mutations or frame-shift mutations (P < 0.01), and UMPP gene non-sense mutations or frame-shift mutations (P = 0.01).
Jade-1: its structure, regulation and functions in the renal cancer.
Review
New
Xuzhou, China. In Curr Mol Med, Dec 2015
Jade-1 is originally identified by the yeast two-hybrid system as a protein partner of von Hippel-Lindau (pVHL) tumor suppressor, a well-known renal tumor suppressor.
E3 Ubiquitin Ligase VHL Regulates Hypoxia-Inducible Factor-1α to Maintain Regulatory T Cell Stability and Suppressive Capacity.
New
Impact
Los Angeles, United States. In Immunity, Jul 2015
Here, we report that the E3 ubiquitin ligase VHL is essential for Treg cell function.
A lactate-induced response to hypoxia.
New
Impact
Taejŏn, South Korea. In Cell, May 2015
We find that the NDRG3 protein is degraded in a PHD2/VHL-dependent manner in normoxia but is protected from destruction by binding to lactate that accumulates under hypoxia.
VHL, the story of a tumour suppressor gene.
Review
Impact
Cambridge, United Kingdom. In Nat Rev Cancer, 2015
VHL tumour suppressor protein (pVHL) plays a key part in cellular oxygen sensing by targeting hypoxia-inducible factors for ubiquitylation and proteasomal degradation.
[Hereditary pheochromocytoma-associated syndromes. Part 1].
Review
In Ter Arkh, 2014
There have been the most investigated NF, RET, VHL, SDHD, SDHC, and SDHB gene mutations.
Von Hippel-Lindau disease.
Review
Bethesda, United States. In Handb Clin Neurol, 2014
von Hippel-Lindau (VHL) disease is an inheritable condition with an incidence of 1 in 36000 live births.
Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicine.
Review
Mannheim, Germany. In Epma J, 2014
The most common molecular markers of kidney cancer include mutations and epigenetic inactivation of von Hippel-Lindau (VHL) gene, genes of vascular endothelial growth factor (VEGF) pathway, and carbonic anhydrase IX (CIAX).
TRPM3 and miR-204 establish a regulatory circuit that controls oncogenic autophagy in clear cell renal cell carcinoma.
Impact
Cincinnati, United States. In Cancer Cell, 2014
The von Hippel-Lindau tumor suppressor (VHL) represses TRPM3 directly through miR-204 and indirectly through another miR-204 target, Caveolin 1 (CAV1).
Von Hippel-Lindau protein in the RPE is essential for normal ocular growth and vascular development.
GeneRIF
London, United Kingdom. In Development, 2012
The data showed that Von Hippel-Lindau protein-dependent regulation of Hif1a in the retinal pigment epithelium is essential for normal retinal pigment epithelial and iris development, ocular growth and vascular development in the anterior chamber.
Systemic VHL gene functions and the VHL disease.
Review
GeneRIF
Boston, United States. In Febs Lett, 2012
functions of VHL likely play important roles in the development of VHL disease
Identification and functional characterization of pVHL-dependent cell surface proteins in renal cell carcinoma.
GeneRIF
Zürich, Switzerland. In Neoplasia, 2012
pVHL-dependent cell surface glycoproteins as potential diagnostic markers for therapeutic targeting and RCC patient monitoring.
Knockdown of von Hippel-Lindau protein decreases lung cancer cell proliferation and colonization.
GeneRIF
Chicago, United States. In Febs Lett, 2012
Knockdown of pVHL decreased phosphorylation of FAK and expression of integrin, suggesting that pVHL regulates lung cancer development via integrin/FAK signaling pathway
[Localization of point mutations in the coding part of the VHL gene in clear cell renal cancer].
More papers using
VHL
antibodies
GeneRIF
In Mol Biol (mosk), 2012
39.1% samples with stage I harbor somatic mutations in VHL gene, however, no association with progression or metastases was found
Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors.
Supplier
In PLoS ONE, 2002
... Conditional VHL knockout mice were generated by crossbreeding three different transgenic mouse lines: a) floxed ...
